Home / Stocks / Kwality Pharmaceuticals L
KPL

Kwality Pharmaceuticals L Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹4,286.6

Change

+78.7 (1.87%)

Open

₹4,230.0

Prev. Close

₹4,207.9

Day High

₹4,299.0

Day Low

₹4,150.0

Volume Analysis

Traded

42,642

Delivered

17,090

Delivery %

40.08%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (3)

  • •Trading within 3% of its 52-week high (₹4240.0)
  • •Strong return on equity (22.6%)
  • •Strong operating margin (26.0%)

Weaknesses (0)

No signal for this stock

Opportunities (3)

  • •Strong 3-year EPS growth (51.5%)
  • •Strong 3-year revenue growth (26.1%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹4,489.4 ₹4,394.2 ₹4,340.4 ₹4,245.2 ₹4,191.4 ₹4,096.2 ₹4,042.4
Fibonacci ₹4,394.2 ₹4,337.28 ₹4,302.12 ₹4,245.2 ₹4,188.28 ₹4,153.12 ₹4,096.2
Camarilla ₹4,327.58 ₹4,313.92 ₹4,300.26 ₹4,245.2 ₹4,272.94 ₹4,259.28 ₹4,245.63

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

+8.56%

1 Month

+25.07%

3 Months

+27.54%

6 Months

+100.55%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹737.09

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

20.04%

Net margin 15.38% × asset turnover 0.72x × equity multiplier 1.81x

Company Overview

Sector

Healthcare

Market Cap

₹4,370 Cr

P/E (TTM)

45.3

ROE

22.6%

Book Value

₹372.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Kwality Pharmaceuticals L holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 67/100. The strongest factor is Momentum (99/100), while Valuation (0/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹4240.0); strong return on equity (22.6%). Strong 3-year EPS growth (51.5%).

TopFund Score — Fundamentals Quality

67/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

95

Growth

92

Valuation

0

Cash Flow

3

Corporate Governance

56

Momentum

99

Institutional Ownership

52

Business Quality

92

Risk & Volatility

80

Liquidity

65

From Screener.in

  • +Company is expected to give good quarter
  • +Company has delivered good profit growth of 34.8% CAGR over last 5 years
  • +Company has a good return on equity (ROE) track record: 3 Years ROE 18.1%
  • +Company's median sales growth is 27.4% of last 10 years
  • −Stock is trading at 11.3 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has high debtors of 203 days.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper Publication of Unaudited Financial Results for the quarter and half year ended September 30, 2026

Audio recording of November 9, 2026 investor earnings call uploaded to company website.

Audio recording of November 9, 2026 earnings call uploaded for Q2 and half-year FY2026 results.

Investor Presentation for the quarter and half year ended unaudited financial results for 30-09-2026

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 70 78 92 80 90 84 116 111 111 123 157 162 181
Expenses + 54 61 71 63 70 67 90 87 86 93 118 121 131
Operating Profit 15 17 21 17 20 18 26 24 25 30 39 41 50
OPM % 22.0% 21.0% 22.0% 22.0% 22.0% 21.0% 22.0% 22.0% 23.0% 24.0% 25.0% 25.0% 27.0%
Other Income + 0 1 -7 0 0 1 1 0 1 0 1 1 1
Interest 2 3 3 2 3 2 2 3 3 2 3 3 3
Depreciation 5 5 5 4 5 5 5 5 5 5 5 5 5
Profit before tax 8 10 6 11 13 11 19 17 18 22 32 34 42
Tax % 24.0% 21.0% 29.0% 25.0% 33.0% 25.0% 24.0% 30.0% 23.0% 28.0% 20.0% 25.0% 31.0%
Net Profit + 6 8 4 8 8 9 14 12 14 16 25 26 29
EPS in Rs 6 7 4 8 8 8 14 12 14 15 24 25 28
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 25 39 34 19 29 8 26 39 23 46 36 46 63

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 52 74 98 137 166 139 262 456 251 307 370 503 624
Expenses + 49 69 89 126 150 125 233 285 190 241 290 385 465
Operating Profit 3 5 9 12 16 14 29 172 61 66 80 118 160
OPM % 6.0% 7.0% 9.0% 8.0% 9.0% 10.0% 11.0% 38.0% 24.0% 22.0% 22.0% 24.0% 26.0%
Other Income + 0 0 1 1 1 4 2 4 -14 -5 2 2 2
Interest 1 1 2 2 2 3 3 3 7 10 10 11 11
Depreciation 1 2 3 3 3 4 6 11 15 20 18 20 20
Profit before tax 1 2 6 7 11 11 21 162 26 31 54 89 130
Tax % 41.0% 48.0% 42.0% 39.0% 31.0% 25.0% 30.0% 26.0% 25.0% 24.0% 26.0% 25.0% —
Net Profit + 1 1 3 4 8 8 15 120 19 24 40 67 96
EPS in Rs 1 2 3 4 7 8 15 116 19 23 38 65 92
Dividend Payout % 0.0% 0.0% 9.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth -12 42 33 40 21 -16 88 74 -45 22 21 36 48

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 15 17 20 19 27 36 51 171 190 214 254 321 376
Borrowings + 8 13 19 26 29 35 41 54 90 98 112 130 146
Other Liabilities + 10 17 26 40 39 52 64 105 70 72 71 130 165
Total Liabilities 37 51 71 96 105 133 166 341 361 394 447 592 698
Fixed Assets + 13 13 17 20 29 43 57 92 120 139 146 156 168
CWIP 0 0 0 0 0 0 3 12 14 0 0 17 33
Investments 1 2 4 5 5 4 5 0 0 0 0 0 0
Other Assets + 24 37 50 70 71 86 102 237 226 255 302 420 497
Total Assets 37 51 71 96 105 133 166 341 361 394 447 592 698
Equity Capital 4 5 5 10 10 10 10 10 10 10 10 10 10

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 1 -3 4 -1 14 6 27 61 41 43 53 17
Cash from Investing Activity + -1 -2 -7 -6 -12 -18 -23 -63 -48 -26 -29 -35
Cash from Financing Activity + 1 6 5 5 -2 12 1 6 1 -17 -14 7
Net Cash Flow 1 0 2 -1 0 0 4 3 -6 -1 10 -11
Free Cash Flow 0 -5 -2 -7 2 -12 3 5 -4 17 28 -29
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 51 -30 76 21 108 62 115 59 78 67 85 32

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 54.76% → 54.86%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 45.22% 45.17% 45.18% 45.15% 45.14% 44.86% 44.86% 44.83% 44.33% 41.99% 41.45% 41.57%
Promoters 54.76% 54.82% 54.82% 54.82% 54.82% 54.82% 54.82% 54.82% 54.82% 54.87% 54.86% 54.86%
FII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.5% 2.79% 3.13% 2.5%
DII 0.01% 0.0% 0.0% 0.02% 0.03% 0.32% 0.33% 0.33% 0.33% 0.36% 0.56% 1.07%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Kwality Pharmaceuticals L (this stock) 4,370 45.3 11.31 22.6%
Gufic Biosciences Ltd. 4,415 55.1 6.21 10.1%
Zota Health Care Limited 4,492 — 7.17 -15.0%
Rpg Life Sciences Ltd 4,220 36.8 6.13 19.3%
Aarti Drugs Ltd. 4,589 19.9 2.73 13.4%
Gujarat Themis Biosyn Ltd 4,659 239.0 4.55 16.2%
Sms Pharmaceuticals Ltd. 4,758 40.7 5.64 14.3%

Which Mutual Funds Hold Kwality Pharmaceuticals L?

Frequently Asked Questions about Kwality Pharmaceuticals L

Community Sentiment

What are other investors saying about Kwality Pharmaceuticals L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.